Bisphosphonates: biological response modifiers in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Bone Metastasis Research

Background:

• Bone recurrence is a significant issue in breast cancer, contributing to skeletal morbidity like pain, fractures, and hypercalcemia.
• Malignant osteopathy involves tumor cells stimulating osteoclast activity, creating a detrimental cycle of bone resorption and tumor growth.

Purpose of the Study:

• To review the role of bisphosphonates in managing breast cancer bone recurrence and skeletal morbidity.
• To evaluate the efficacy of different bisphosphonates in treating hypercalcemia and reducing skeletal complications.

Main Methods:

• Review of bisphosphonate mechanisms of action, including nitrogen-containing and non-nitrogen-containing agents.
• Analysis of clinical trial data, focusing on adjuvant bisphosphonate use in breast cancer patients.
• Examination of bisphosphonates for treating hypercalcemia and bone pain in metastatic breast cancer.

Main Results:

• Bisphosphonates inhibit bone resorption and may possess anticancer properties, interrupting the cycle of malignant osteopathy.
• Intravenous pamidronate and zoledronate effectively normalize calcium levels in hypercalcemia.
• Oral clodronate in a large trial reduced skeletal metastases incidence and improved 5-year survival in breast cancer patients.

Conclusions:

• Bisphosphonates are valuable in managing skeletal morbidity associated with breast cancer bone metastases.
• Adjuvant oral clodronate demonstrated a significant reduction in skeletal metastases and improved survival, highlighting its therapeutic potential.